Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more
Intervacc AB (IVACC) - Total Liabilities
Latest total liabilities as of September 2025: Skr18.76 Million SEK
Based on the latest financial reports, Intervacc AB (IVACC) has total liabilities worth Skr18.76 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intervacc AB - Total Liabilities Trend (2013–2024)
This chart illustrates how Intervacc AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Intervacc AB Competitors by Total Liabilities
The table below lists competitors of Intervacc AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kapston Services Limited
NSE:KAPSTON
|
India | ₹2.21 Billion |
|
Malmbergs Elektriska AB (publ)
ST:MEAB-B
|
Sweden | Skr157.75 Million |
|
Smart Digital Group Limited Ordinary Shares
NASDAQ:SDM
|
USA | $7.15 Million |
|
Surgepays Inc
NASDAQ:SURG
|
USA | $20.92 Million |
|
Koryo Electronics Co Ltd
TWO:8032
|
Taiwan | NT$1.19 Billion |
|
Mestron Holdings
KLSE:0207
|
Malaysia | RM48.34 Million |
|
Orient Bell Limited
NSE:ORIENTBELL
|
India | ₹1.98 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Intervacc AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intervacc AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intervacc AB (2013–2024)
The table below shows the annual total liabilities of Intervacc AB from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr24.99 Million | +15.26% |
| 2023-12-31 | Skr21.68 Million | +45.74% |
| 2022-12-31 | Skr14.88 Million | -29.63% |
| 2021-12-31 | Skr21.14 Million | +19.63% |
| 2020-12-31 | Skr17.67 Million | +2.48% |
| 2019-12-31 | Skr17.25 Million | +40.97% |
| 2018-12-31 | Skr12.23 Million | -17.03% |
| 2017-12-31 | Skr14.74 Million | -55.95% |
| 2016-12-31 | Skr33.47 Million | +17.72% |
| 2015-12-31 | Skr28.44 Million | -46.08% |
| 2014-12-31 | Skr52.74 Million | +4143.19% |
| 2013-12-31 | Skr1.24 Million | -- |